These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 24488530)

  • 1. Exploring the human tear fluid: discovery of new biomarkers in multiple sclerosis.
    Salvisberg C; Tajouri N; Hainard A; Burkhard PR; Lalive PH; Turck N
    Proteomics Clin Appl; 2014 Apr; 8(3-4):185-94. PubMed ID: 24488530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of tear fluid biomarkers in dry eye syndrome using iTRAQ quantitative proteomics.
    Zhou L; Beuerman RW; Chan CM; Zhao SZ; Li XR; Yang H; Tong L; Liu S; Stern ME; Tan D
    J Proteome Res; 2009 Nov; 8(11):4889-905. PubMed ID: 19705875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion.
    Calais G; Forzy G; Crinquette C; Mackowiak A; de Seze J; Blanc F; Lebrun C; Heinzlef O; Clavelou P; Moreau T; Hennache B; Zephir H; Verier A; Neuville V; Confavreux C; Vermersch P; Hautecoeur P
    Mult Scler; 2010 Jan; 16(1):87-92. PubMed ID: 20028709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid-associated orbitopathy and tears: A proteomics study.
    Kishazi E; Dor M; Eperon S; Oberic A; Hamedani M; Turck N
    J Proteomics; 2018 Jan; 170():110-116. PubMed ID: 28887209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomics characterization of extracellular vesicles sorted by flow cytometry reveals a disease-specific molecular cross-talk from cerebrospinal fluid and tears in multiple sclerosis.
    Pieragostino D; Lanuti P; Cicalini I; Cufaro MC; Ciccocioppo F; Ronci M; Simeone P; Onofrj M; van der Pol E; Fontana A; Marchisio M; Del Boccio P
    J Proteomics; 2019 Jul; 204():103403. PubMed ID: 31170500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis.
    Tumani H; Lehmensiek V; Rau D; Guttmann I; Tauscher G; Mogel H; Palm C; Hirt V; Suessmuth SD; Sapunova-Meier I; Ludolph AC; Brettschneider J
    Neurosci Lett; 2009 Mar; 452(2):214-7. PubMed ID: 19383442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM.
    Kroksveen AC; Aasebø E; Vethe H; Van Pesch V; Franciotta D; Teunissen CE; Ulvik RJ; Vedeler C; Myhr KM; Barsnes H; Berven FS
    J Proteomics; 2013 Jan; 78():312-25. PubMed ID: 23059536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten years of proteomics in multiple sclerosis.
    Farias AS; Pradella F; Schmitt A; Santos LM; Martins-de-Souza D
    Proteomics; 2014 Mar; 14(4-5):467-80. PubMed ID: 24339438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers.
    Ottervald J; Franzén B; Nilsson K; Andersson LI; Khademi M; Eriksson B; Kjellström S; Marko-Varga G; Végvári A; Harris RA; Laurell T; Miliotis T; Matusevicius D; Salter H; Ferm M; Olsson T
    J Proteomics; 2010 Apr; 73(6):1117-32. PubMed ID: 20093204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevation of human alpha-defensins and S100 calcium-binding proteins A8 and A9 in tear fluid of patients with pterygium.
    Zhou L; Beuerman RW; Ang LP; Chan CM; Li SF; Chew FT; Tan DT
    Invest Ophthalmol Vis Sci; 2009 May; 50(5):2077-86. PubMed ID: 19168894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated Lipidomics and Metabolomics Analysis of Tears in Multiple Sclerosis: An Insight into Diagnostic Potential of Lacrimal Fluid.
    Cicalini I; Rossi C; Pieragostino D; Agnifili L; Mastropasqua L; di Ioia M; De Luca G; Onofrj M; Federici L; Del Boccio P
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30871169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis.
    Hinsinger G; Galéotti N; Nabholz N; Urbach S; Rigau V; Demattei C; Lehmann S; Camu W; Labauge P; Castelnovo G; Brassat D; Loussouarn D; Salou M; Laplaud D; Casez O; Bockaert J; Marin P; Thouvenot E
    Mult Scler; 2015 Sep; 21(10):1251-61. PubMed ID: 25698171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-based profiling of cerebrospinal fluid within multiple sclerosis.
    Häggmark A; Byström S; Ayoglu B; Qundos U; Uhlén M; Khademi M; Olsson T; Schwenk JM; Nilsson P
    Proteomics; 2013 Aug; 13(15):2256-67. PubMed ID: 23696371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis.
    Kroksveen AC; Jaffe JD; Aasebø E; Barsnes H; Bjørlykke Y; Franciotta D; Keshishian H; Myhr KM; Opsahl JA; van Pesch V; Teunissen CE; Torkildsen Ø; Ulvik RJ; Vethe H; Carr SA; Berven FS
    Proteomics; 2015 Oct; 15(19):3361-9. PubMed ID: 26152395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic profiling of inflammatory signaling molecules in the tears of patients on chronic glaucoma medication.
    Wong TT; Zhou L; Li J; Tong L; Zhao SZ; Li XR; Yu SJ; Koh SK; Beuerman RW
    Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7385-91. PubMed ID: 21697136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis.
    Avsar T; Korkmaz D; Tütüncü M; Demirci NO; Saip S; Kamasak M; Siva A; Turanli ET
    Mult Scler; 2012 Aug; 18(8):1081-91. PubMed ID: 22252467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unraveling the molecular repertoire of tears as a source of biomarkers: beyond ocular diseases.
    Pieragostino D; D'Alessandro M; di Ioia M; Di Ilio C; Sacchetta P; Del Boccio P
    Proteomics Clin Appl; 2015 Feb; 9(1-2):169-86. PubMed ID: 25488355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of natalizumab treatment on the cerebrospinal fluid proteome of multiple sclerosis patients.
    Stoop MP; Singh V; Stingl C; Martin R; Khademi M; Olsson T; Hintzen RQ; Luider TM
    J Proteome Res; 2013 Mar; 12(3):1101-7. PubMed ID: 23339689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis.
    Salazar IL; Lourenço AST; Manadas B; Baldeiras I; Ferreira C; Teixeira AC; Mendes VM; Novo AM; Machado R; Batista S; Macário MDC; Grãos M; Sousa L; Saraiva MJ; Pais AACC; Duarte CB
    J Neuroinflammation; 2022 Feb; 19(1):44. PubMed ID: 35135578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tear proteomic analysis of patients with type 2 diabetes and dry eye syndrome by two-dimensional nano-liquid chromatography coupled with tandem mass spectrometry.
    Li B; Sheng M; Xie L; Liu F; Yan G; Wang W; Lin A; Zhao F; Chen Y
    Invest Ophthalmol Vis Sci; 2014 Jan; 55(1):177-86. PubMed ID: 24282230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.